R848@M2pep-MPsAFP treatment also significantly increased the numbers of the activated CD8+CD69+ T cells (Supplementary Fig. 25a), CD8+IFNγ+ T cells (Supplementary Fig. 25b) and CD8+GzmB+ T cells (Supplementary Fig. 25c) in spleens of orthotopic Hepa1-6 tumor-bearing mice, suggesting that R848@M2pep-MPsAFP efficiently activated the systemic antitumor immunity. The gene discussed is CD8A; the disease is neoplasm.